Figures & data
Murray A, Nguyen TM, Parker CE, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8:CD000543. Murray A, Nguyen TM, Parker CE, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8:CD000544. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993;88:1188–1197. Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16(9):1567–1574. Gibson PR, Fixa B, Pekarkova B, et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2006;23(7):1017–1026. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132(1):66–75. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5(1):95–102. Feagan BG, Sandborn WJ, D’Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013;145(1):149–157.e2. Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digest Dis Sci. 1995;40(2):296–304. Desideri S, Ardizzone S, Petrillo M. Two different oral formulations of 5-Aminosalicylic acid (5-ASA) in maintenance treatment of ulcerative colitis. Ital J Gastroenterol. 1991;23:643. Mulder CJJ, Tytgat GNJ, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylateand sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology. 1988;95(6):1449–1453. Campieri M, Gionchetti PB, et al. Slow-release 5-aminosalicylic acid (PENTASA) versus sulphasalazine (SASP) in the maintenance treatment of ulcerative colitise. Scand J Gastroenterol. 1989;24:130. Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16(9):1575–1582. Nagahori M, Kochi S, Hanai H, et al. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. BMC Gastroenterol. 2017;17(1):47. Data availability statement
All data relevant to the study are included in the article or uploaded as online supplemental information.